Met signaling in cardiomyocytes is required for normal cardiac function in adult mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2204-2215

  Arechederra, María ^a   Carmona, Rita ^b   González Nuñez, María ^c   Gutiérrez Uzquiza, Álvaro ^a   Bragado, Paloma ^a   Cruz González, Ignacio ^d   Cano, Elena ^b   Guerrero, Carmen ^e   Sánchez, Aránzazu ^a   López Novoa, José Miguel ^c   Schneider, Michael D ^f   Maina, Flavio ^g   Muñoz Chápuli, Ramón ^b   Porras, Almudena ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e CSIC   (Spain)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Cardiomyocytes; Heart; Hepatocyte growth factor; Met; Oxidative stress; P38MAPK

Indexed keywords

ANTIOXIDANT; CATALASE; CRE RECOMBINASE; CYTOCHROME C OXIDASE; MYOSIN HEAVY CHAIN ALPHA; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; HEART DEVELOPMENT; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION;

EID: 84884139236     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.08.008     Document Type: Article

References (59)

1. Birchmeier C., Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998, 8:404-410.
2. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11:834-848.
3. Ma P.C., Maulik G., Christensen J., Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003, 22:309-325.
4. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
5. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
6. Maina F., Casagranda F., Audero E., Simeone A., Comoglio P.M., Klein R., Ponzetto C. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996, 87:531-542.
7. Maina F., Hilton M.C., Andres R., Wyatt S., Klein R., Davies A.M. Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 1998, 2:835-846.
8. Maina F., Hilton M.C., Ponzetto C., Davies A.M., Klein R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 1997, 11:3341-3350.
9. Maina F., Panté G., Helmbacher F., Andres R., Porthin A., Davies A.M., Ponzetto C., Klein R. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 2001, 7:1293-1306.
10. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702.
11. Ueda H., Nakamura T., Matsumoto K., Sawa Y., Matsuda H., Nakamura T. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc. Res. 2001, 51:41-50.
12. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H., Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519.
13. Li Y., Takemura G., Kosai K., Yuge K., Nagano S., Esaki M., Goto K., Takahashi T., Hayakawa K., Koda M., Kawase Y., Maruyama R., Okada H., Minatoguchi S., Mizuguchi H., Fujiwara T., Fujiwara H. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003, 107:2499-2506.
14. Iwasaki M., Adachi Y., Nishiue T., Minamino K., Suzuki Y., Zhang Y., Nakano K., Koike Y., Wang J., Mukaide H., Taketani S., Yuasa F., Tsubouchi H., Gohda E., Iwasaka T., Ikehara S. Hepatocyte growth factor delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricular contractile function in doxorubicin-induced cardiomyopathy. Stem Cells 2005, 23:1589-1597.
15. Nakamura T., Matsumoto K., Mizuno S., Sawa Y., Matsuda H., Nakamura T. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2131-H2139.
16. Sala V., Crepaldi T. Novel therapy for myocardial infaction: can HGF/Met be beneficial?. Cell. Mol. Life Sci. 2011, 68:1703-1717.
17. Forte G., Minieri M., Cossa P., Antenucci D., Sala M., Gnocchi V., Fiaccavento R., Carotenuto F., De Vito P., Baldini P.M., Prat M., Di Nardo P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006, 24:23-33.
18. Roggia C., Ukena C., Böhm M., Kilter H. Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp. Cell Res. 2007, 313:921-930.
19. Rappolee D.A., Iyer A., Patel Y. Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis. Circ. Res. 1996, 78:1028-1036.
20. Song W., Majka S.M., McGuire P.G. Hepatocyte growth factor expression in the developing myocardium: evidence for a role in the regulation of the mesenchymal cell phenotype and urokinase expression. Dev. Dyn. 1999, 214:92-100.
21. Leo C., Sala V., Morello M., Chiribiri A., Riess I., Mancardi D., Schiaffino S., Ponzetto C., Crepaldi T. Activated Met signalling in the developing mouse heart leads to cardiac disease. PLoS One 2011, 6:e14675.
22. Huh C.G., Factor V.M., Sánchez A., Uchida K., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4477-4482.
23. Agah R., Frenkel P.A., French B.A., Michael L.H., Overbeek P.A., Schneider M.D. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J. Clin. Invest. 1997, 100:169-179.
24. Lyons G.E., Schiaffino S., Sassoon D., Barton P., Buckingham M. Developmental regulation of myosin gene expression in mouse cardiac muscle. J. Cell Biol. 1990, 111:2427-2436.
25. Zammit P.S., Kelly R.G., Franco D., Brown N., Moorman A.F., Buckingham M.E. Suppression of atrial myosin gene expression occurs independently in the left and right ventricles of the developing mouse heart. Dev. Dyn. 2000, 217:75-85.
26. Zuluaga S., Alvarez-Barrientos A., Gutiérrez-Uzquiza A., Benito M., Nebreda A.R., Porras A. Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell. Signal. 2007, 19:62-74.
27. Richert S., Wehr N., Stadtman E., Levine R. Assessment of skin carbonyl content as a noninvasive measure of biological age. Arch. Biochem. Biophys. 2002, 397:430-432.
28. Grande M.T., Pascual G., Riolobos A.S., Clemente-Lorenzo M., Bardaji B., Barreiro L., Tornavaca O., Meseguer A., López-Novoa J.M. Increased oxidative stress, the renin-angiotensin system, and sympathetic overactivation induce hypertension in kidney androgen-regulated protein transgenic mice. Free Radic. Biol. Med. 2011, 51:1831-1841.
29. Adams R.H., Porras A., Alonso G., Jones M., Vintersten K., Panelli S., Valladares A., Pérez L., Klein R., Nebreda A.R. Essential role of p38 α MAP Kinase in placental but not embryonic cardiovascular development. Mol. Cell 2000, 6:109-116.
30. Buerger A., Rozhitskaya O., Sherwood M.C., Dorfman A.L., Bisping E., Abel E.D., Pu W.T., Izumo S., Jay P.Y. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J. Card. Fail. 2006, 12:392-398.
31. Gascon E., Gaillard S., Malapert P., Liu Y., Rodat-Despoix L., Samokhvalov I.M., Delmas P., Helmbacher F., Maina F., Moqrich A. Hepatocyte growth factor-Met signaling is required for Runx1 extinction and peptidergic differentiation in primary nociceptive neurons. J. Neurosci. 2010, 30:12414-12423.
32. Lamballe F., Genestine M., Caruso N., Arce V., Richelme S., Helmbacher F., Maina F. Pool-specific regulation of motor neuron survival by neurotrophic support. J. Neurosci. 2011, 31:11144-11158.
33. Deschamps A.M., Murphy E., Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med. 2010, 20:73-78.
34. Kararigas G., Fliegner D., Gustafsson J.Å., Regitz-Zagrosek V. Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy. Physiol. Genomics 2011, 43:438-446.
35. Murphy E., Steenbergen C. Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 2007, 75:478-486.
36. Rohini A., Agrawal N., Koyani C.N., Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol. Res. 2010, 61:269-280.
37. Barry S.P., Davidson S.M., Townsend P.A. Molecular regulation of cardiac hypertrophy. Int. J. Biochem. Cell Biol. 2008, 40:2023-2039.
38. Liu G., Iden J.B., Kovithavongs K., Gulamhusein R., Duff H.J., Kavanagh K.M. In vivo temporal and spatial distribution of depolarization and repolarization and the illusive murine T wave. J. Physiol. 2003, 555:267-279.
39. Dai D.F., Rabinovitch P.S. Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc. Med. 2009, 19:213-220.
40. Gómez-Quiroz L.E., Factor V.M., Kaposi-Novak P., Coulouarn C., Conner E.A., Thorgeirsson S.S. Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis. J. Biol. Chem. 2008, 283:14581-14589.
41. Takami T., Kaposi-Novak P., Uchida K., Gomez-Quiroz L.E., Conner E.A., Factor V.M., Thorgeirsson S.S. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 2007, 67:9844-9851.
42. Valdés-Arzate A., Luna A., Bucio L., Licona C., Clemens D.L., Souza V., Hernandez E., Kershenobich D., Gutiérrez-Ruiz M.C., Gómez-Quiroz L.E. Hepatocyte growth factor protects hepatocytes against oxidative injury induced by ethanol metabolism. Free Radic. Biol. Med. 2009, 47:424-430.
43. Gutiérrez-Uzquiza A., Arechederra M., Bragado P., Aguirre-Ghiso J.A., Porras A. p38alpha mediates cell survival in response to oxidative stress via induction of antioxidant genes. Effect on the p70S6K pathway. J. Biol. Chem. 2012, 287:2632-2642.
44. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 2009, 119:2758-2771.
45. Krenek P., Kmecova J., Kucerova D., Bajuszova Z., Musil P., Gazova A., Ochodnicky P., Klimas J., Kyselovic J. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur. J. Heart Fail. 2009, 11:140-146.
46. Kondo I., Ohmori K., Oshita A., Takeuchi H., Fuke S., Shinomiya K., Noma T., Namba T., Kohno M. Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. J. Am. Coll. Cardiol. 2004, 44:644-653.
47. Bailey B., Izarra A., Alvarez R., Fischer K.M., Cottage C.T., Quijada P., Díez-Juan A., Sussman M.A. Cardiac stem cell genetic engineering using the alphaMHC promoter. Regen. Med. 2009, 4:823-833.
48. Linke A., Müller P., Nurzynska D., Casarsa C., Torella D., Nascimbene A., Castaldo C., Cascapera S., Böhm M., Quaini F., Urbanek K., Leri A., Hintze T.H., Kajstura J., Anversa P. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8966-8971.
49. Urbanek K., Rota M., Cascapera S., Bearzi C., Nascimbene A., De Angelis A., Hosoda T., Chimenti S., Baker M., Limana F., Nurzynska D., Torella D., Rotatori F., Rastaldo R., Musso E., Quaini F., Leri A., Kajstura J., Anversa P. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res. 2005, 97:663-673.
50. Kitta K., Day R.M., Ikeda T., Suzuki Y.J. Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis. Free Radic. Biol. Med. 2001, 31:902-910.
51. Santos C.X.C., Anilkumar N., Zhang M., Brewer A.C., Shah A.M. Redox signaling in cardiac myocytes. Free Radic. Biol. Med. 2011, 50:777-793.
52. Gustafsson A.B., Gottlieb R.A. Heart mitochondria: gates of life and death. Cardiovasc. Res. 2008, 77:334-343.
53. Genestine M., Caricati E., Fico A., Richelme S., Hassani H., Sunyach C., Lamballe F., Panzica G.C., Pettmann B., Helmbacher F., Raoul C., Maina F., Dono R. Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Differ. 2011, 2:e130.
54. Xia S., Laterra J. Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells. Biochem. Biophys. Res. Commun. 2006, 345:1358-1364.
55. Ide T., Tsutsui H., Hayashidani S., Kang D., Suematsu N., Nakamura K., Utsumi H., Hamasaki N., Takeshita A. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ. Res. 2001, 88:529-535.
56. Tsutsui H., Kinugawa S., Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodeling. Cardiovasc. Res. 2009, 81:449-456.
57. Li Y., Huang T.T., Carlson E.J., Melov S., Ursell P.C., Olson J.L., Noble L.J., Yoshimura M.P., Berger C., Chan P.H., Wallace D.C., Epstein C.J. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 1995, 11:376-381.
58. Furlan A., Stagni V., Hussain A., Richelme S., Conti F., Prodosmo A., Destro A., Roncalli M., Barilà D., Maina F. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ. 2011, 18:1608-1616.
59. Furlan A., Lamballe F., Stagni V., Hussain A., Richelme S., Prodosmo A., Moumen A., Brun C., del Barco Barrantes I., Arthur J.S.C., koleske A.J., Nebreda A.R., Barilà D., Maina F. Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. J. Hepatol. 2012, 57:1292-1298.